This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Southern, J.
Right arrow Articles by Miller, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Southern, J.
Right arrow Articles by Miller, E.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, February 2009, p. 194-199, Vol. 16, No. 2
1071-412X/09/$08.00+0     doi:10.1128/CVI.00420-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Immunogenicity of a Reduced Schedule of Meningococcal Group C Conjugate Vaccine Given Concomitantly with the Prevenar and Pediacel Vaccines in Healthy Infants in the United Kingdom{triangledown}

Jo Southern,1 Ray Borrow,2* Nick Andrews,3 Rhonwen Morris,4 Pauline Waight,1 Michael Hudson,5 Paul Balmer,2 Helen Findlow,2 Jamie Findlow,2 and Elizabeth Miller1

Immunisation Department, Centre for Infections, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom,1 Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom,2 Statistics, Modeling and Economics Department, Centre for Infections, Health Protection Agency, Colindale, London NW9 5EQ, United Kingdom,3 Gloucester Vaccine Evaluation Unit, Health Protection Agency, Gloucestershire Royal Hospital, Gloucester, United Kingdom,4 Immunoassay Laboratory, Centre for Emergency Preparedness and Response, Health Protection Agency, Porton Down, Salisbury, United Kingdom5

Received 14 November 2008/ Returned for modification 8 December 2008/ Accepted 9 December 2008

This study investigated the use of two doses of three different meningococcal group C conjugate (MCC) vaccines when given for primary immunization with a seven-valent pneumococcal conjugate vaccine (PCV7) and Pediacel, a combination product containing five acellular pertussis components, diphtheria and tetanus toxoids, Haemophilus influenzae type b (Hib) conjugate, and inactivated-poliovirus vaccine. The immune response after a single dose of MCC is also presented. Infants were randomized to receive two doses of one of the MCC vaccines and PCV7 at 2 and 3 months or at 2 and 4 months of age. Meningococcal group C serum bactericidal antibody (SBA) geometric mean titers, Hib-polyribosylribitol phosphate (PRP) immunoglobulin G (IgG) geometric mean concentrations (GMCs), and diphtheria and tetanus antitoxin GMCs, together with the proportions of infants achieving putative protective levels, were determined. A total of 393 infants were recruited. Following the first dose of NeisVac-C (MCC conjugated to tetanus toxoid), 97% of infants achieved protective levels (SBA titer of ≥8), compared with 80% and 53%, respectively, for Menjugate and Meningitec (both of which are conjugated to CRM197). SBA responses to MCC vaccines were not significantly different when administered at 2 and 3 or 2 and 4 months of age. Following two doses of each MCC, 98 to 100% of infants achieved protective levels. Both PRP IgG and tetanus responses were significantly enhanced when Pediacel was coadministered with NeisVac-C. This study demonstrates that NeisVac-C and Menjugate generate good immunogenicity after the first dose at 2 months of age when coadministered with PCV7 and Pediacel and merit further investigation in single-dose priming strategies.

* Corresponding author. Mailing address: Vaccine Evaluation Unit, Health Protection Agency, Manchester Medical Microbiology Partnership, P.O. Box 209, Clinical Sciences Building 2, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom. Phone: 44 (0) 161 276 6793. Fax: 44 (0) 161 276 6792. E-mail: ray.borrow{at}hpa.org.uk

{triangledown} Published ahead of print on 17 December 2008.

Clinical and Vaccine Immunology, February 2009, p. 194-199, Vol. 16, No. 2
1071-412X/09/$08.00+0     doi:10.1128/CVI.00420-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • de Voer, R. M., van der Klis, F. R. M., Niers, L. E. M., Rijkers, G. T., Berbers, G. A. M. (2009). Absence of Neisseria meningitidis Serogroup C-Specific Antibodies during the First Year of Life in The Netherlands: an Age Group at Risk?. CVI 16: 1521-1523 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»